Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Liver Transplantation | 90 | 2022 | 1175 | 6.320 |
Why?
|
Immunosuppressive Agents | 29 | 2021 | 975 | 1.520 |
Why?
|
Islets of Langerhans Transplantation | 12 | 2021 | 241 | 1.490 |
Why?
|
Living Donors | 14 | 2022 | 339 | 1.480 |
Why?
|
Graft Rejection | 39 | 2014 | 1060 | 1.390 |
Why?
|
Hepatectomy | 12 | 2011 | 170 | 1.360 |
Why?
|
Liver Diseases | 11 | 2014 | 242 | 1.280 |
Why?
|
Tacrolimus | 19 | 2014 | 369 | 1.210 |
Why?
|
Portal Vein | 7 | 2018 | 120 | 1.100 |
Why?
|
Graft Survival | 31 | 2018 | 894 | 1.030 |
Why?
|
Tissue Donors | 12 | 2016 | 489 | 0.970 |
Why?
|
Postoperative Complications | 22 | 2022 | 2271 | 0.910 |
Why?
|
Liver Neoplasms | 12 | 2010 | 754 | 0.910 |
Why?
|
Kidney Transplantation | 24 | 2012 | 849 | 0.870 |
Why?
|
Tissue and Organ Procurement | 10 | 2022 | 343 | 0.840 |
Why?
|
Surgical Mesh | 4 | 2007 | 122 | 0.830 |
Why?
|
Pancreas Transplantation | 10 | 2006 | 104 | 0.830 |
Why?
|
Hepatic Artery | 7 | 2006 | 84 | 0.760 |
Why?
|
Organ Transplantation | 5 | 2017 | 274 | 0.760 |
Why?
|
Humans | 160 | 2022 | 88715 | 0.730 |
Why?
|
Islets of Langerhans | 6 | 2018 | 548 | 0.660 |
Why?
|
Liver, Artificial | 4 | 2002 | 7 | 0.640 |
Why?
|
Quality Improvement | 1 | 2022 | 444 | 0.640 |
Why?
|
Liver Failure | 4 | 2004 | 67 | 0.630 |
Why?
|
Abdominal Cavity | 2 | 2007 | 18 | 0.580 |
Why?
|
Adult | 75 | 2021 | 26386 | 0.580 |
Why?
|
Hernia, Inguinal | 2 | 2006 | 70 | 0.490 |
Why?
|
End Stage Liver Disease | 1 | 2015 | 60 | 0.480 |
Why?
|
Child | 42 | 2022 | 7108 | 0.470 |
Why?
|
Wounds, Gunshot | 2 | 2021 | 84 | 0.440 |
Why?
|
Muromonab-CD3 | 11 | 1998 | 69 | 0.430 |
Why?
|
Follow-Up Studies | 26 | 2018 | 3647 | 0.430 |
Why?
|
Liver | 11 | 2022 | 1204 | 0.430 |
Why?
|
Insulin-Secreting Cells | 4 | 2019 | 403 | 0.430 |
Why?
|
Sirolimus | 1 | 2014 | 170 | 0.420 |
Why?
|
Cyclosporine | 10 | 1998 | 237 | 0.420 |
Why?
|
Hepatocytes | 3 | 2002 | 119 | 0.420 |
Why?
|
Male | 74 | 2021 | 42068 | 0.410 |
Why?
|
Polyethylene Glycols | 2 | 2014 | 358 | 0.400 |
Why?
|
Female | 67 | 2022 | 45827 | 0.400 |
Why?
|
Prostheses and Implants | 2 | 2010 | 125 | 0.390 |
Why?
|
Intestines | 1 | 2014 | 416 | 0.380 |
Why?
|
Veterans | 1 | 2011 | 83 | 0.380 |
Why?
|
Diabetes Mellitus, Type 1 | 5 | 2021 | 559 | 0.370 |
Why?
|
T-Lymphocytes, Regulatory | 4 | 2014 | 305 | 0.350 |
Why?
|
Obesity | 2 | 2019 | 956 | 0.350 |
Why?
|
Stents | 4 | 2021 | 395 | 0.350 |
Why?
|
Duodenum | 3 | 2006 | 103 | 0.340 |
Why?
|
Lysine | 1 | 2010 | 150 | 0.340 |
Why?
|
Child, Preschool | 26 | 2016 | 3690 | 0.330 |
Why?
|
Time Factors | 28 | 2015 | 5309 | 0.320 |
Why?
|
Middle Aged | 47 | 2021 | 25741 | 0.320 |
Why?
|
Jaundice, Obstructive | 1 | 2008 | 10 | 0.320 |
Why?
|
Carcinoma, Hepatocellular | 6 | 2010 | 390 | 0.310 |
Why?
|
Crohn Disease | 2 | 2014 | 754 | 0.310 |
Why?
|
Jejunum | 2 | 2006 | 80 | 0.310 |
Why?
|
Liver Abscess | 1 | 2007 | 12 | 0.300 |
Why?
|
Fasting | 2 | 2018 | 163 | 0.300 |
Why?
|
Silicones | 1 | 2007 | 16 | 0.300 |
Why?
|
Treatment Outcome | 20 | 2015 | 8170 | 0.300 |
Why?
|
Hemangioma, Cavernous | 1 | 2008 | 69 | 0.300 |
Why?
|
Dimethylpolysiloxanes | 1 | 2007 | 15 | 0.300 |
Why?
|
Kidney | 5 | 2007 | 1145 | 0.300 |
Why?
|
Health Care Reform | 1 | 2008 | 85 | 0.300 |
Why?
|
Pyelonephritis, Xanthogranulomatous | 1 | 2007 | 2 | 0.290 |
Why?
|
Minocycline | 1 | 2007 | 15 | 0.290 |
Why?
|
Duodenal Diseases | 1 | 2007 | 23 | 0.290 |
Why?
|
Patient Selection | 3 | 2020 | 682 | 0.280 |
Why?
|
Liver Failure, Acute | 1 | 2007 | 39 | 0.280 |
Why?
|
Infant | 21 | 2015 | 3128 | 0.280 |
Why?
|
Diverticulum | 1 | 2007 | 45 | 0.280 |
Why?
|
Rectal Diseases | 1 | 2006 | 24 | 0.280 |
Why?
|
Bacterial Infections | 2 | 2005 | 183 | 0.270 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 4 | 2005 | 43 | 0.270 |
Why?
|
Anti-Bacterial Agents | 3 | 2007 | 781 | 0.270 |
Why?
|
Adolescent | 30 | 2021 | 9190 | 0.270 |
Why?
|
Antiviral Agents | 3 | 2022 | 474 | 0.270 |
Why?
|
Colonic Diseases | 1 | 2006 | 61 | 0.270 |
Why?
|
Tendons | 1 | 2006 | 44 | 0.270 |
Why?
|
Peritoneal Dialysis, Continuous Ambulatory | 1 | 2005 | 9 | 0.260 |
Why?
|
Hepatic Veins | 2 | 2002 | 26 | 0.260 |
Why?
|
Foreign Bodies | 1 | 2006 | 65 | 0.260 |
Why?
|
Bioprosthesis | 1 | 2005 | 39 | 0.260 |
Why?
|
Anesthesia, Local | 1 | 2005 | 27 | 0.260 |
Why?
|
Ileostomy | 1 | 2005 | 29 | 0.260 |
Why?
|
Retrospective Studies | 30 | 2016 | 8932 | 0.250 |
Why?
|
Prosthesis-Related Infections | 1 | 2005 | 60 | 0.250 |
Why?
|
Graft Occlusion, Vascular | 3 | 2002 | 99 | 0.240 |
Why?
|
Transplantation, Homologous | 17 | 2013 | 991 | 0.240 |
Why?
|
Prosthesis Implantation | 1 | 2005 | 126 | 0.240 |
Why?
|
Cyclic GMP | 1 | 2004 | 59 | 0.230 |
Why?
|
Catheterization | 1 | 2005 | 238 | 0.230 |
Why?
|
Pancreatitis, Chronic | 2 | 2015 | 54 | 0.230 |
Why?
|
Survival Rate | 15 | 2014 | 1874 | 0.230 |
Why?
|
Pancreas | 4 | 2018 | 243 | 0.230 |
Why?
|
Morbidity | 2 | 2022 | 148 | 0.220 |
Why?
|
Prospective Studies | 12 | 2021 | 4253 | 0.220 |
Why?
|
Bile Ducts | 2 | 2002 | 59 | 0.220 |
Why?
|
Extracorporeal Circulation | 1 | 2002 | 34 | 0.220 |
Why?
|
Ultrasonography, Doppler | 2 | 2002 | 85 | 0.220 |
Why?
|
Blood Loss, Surgical | 2 | 2001 | 115 | 0.210 |
Why?
|
Cholecystectomy | 1 | 2002 | 21 | 0.210 |
Why?
|
China | 4 | 2015 | 232 | 0.210 |
Why?
|
Cannabidiol | 1 | 2022 | 7 | 0.210 |
Why?
|
Pancreatectomy | 3 | 2018 | 157 | 0.210 |
Why?
|
Thrombosis | 4 | 2002 | 301 | 0.200 |
Why?
|
Rectus Abdominis | 2 | 2013 | 40 | 0.200 |
Why?
|
Hepatitis C | 4 | 2012 | 170 | 0.200 |
Why?
|
Abdominal Wall | 2 | 2013 | 30 | 0.200 |
Why?
|
Mortality | 1 | 2022 | 149 | 0.200 |
Why?
|
Head Injuries, Penetrating | 1 | 2022 | 55 | 0.200 |
Why?
|
Monitoring, Physiologic | 1 | 2002 | 266 | 0.190 |
Why?
|
Vascularized Composite Allotransplantation | 1 | 2021 | 14 | 0.190 |
Why?
|
Intraoperative Complications | 1 | 2002 | 188 | 0.180 |
Why?
|
Hypertension, Portal | 3 | 1998 | 46 | 0.180 |
Why?
|
Prognosis | 8 | 2018 | 3750 | 0.180 |
Why?
|
Perfusion | 2 | 2022 | 234 | 0.180 |
Why?
|
Brain Injuries, Traumatic | 1 | 2022 | 98 | 0.180 |
Why?
|
Policy | 1 | 2020 | 35 | 0.170 |
Why?
|
Biliary Tract Diseases | 2 | 1997 | 36 | 0.170 |
Why?
|
Host-Pathogen Interactions | 1 | 2022 | 236 | 0.170 |
Why?
|
Prisoners | 2 | 2011 | 45 | 0.170 |
Why?
|
Vena Cava, Inferior | 1 | 2021 | 144 | 0.170 |
Why?
|
Waiting Lists | 4 | 2007 | 183 | 0.170 |
Why?
|
Thrombectomy | 1 | 2021 | 173 | 0.170 |
Why?
|
Bile Duct Neoplasms | 2 | 2018 | 90 | 0.170 |
Why?
|
Hepatitis B | 5 | 2010 | 75 | 0.170 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2012 | 442 | 0.160 |
Why?
|
Reperfusion Injury | 2 | 1997 | 140 | 0.160 |
Why?
|
Biological Products | 1 | 2021 | 149 | 0.160 |
Why?
|
Absorptiometry, Photon | 1 | 2019 | 99 | 0.160 |
Why?
|
Reoperation | 15 | 1999 | 598 | 0.160 |
Why?
|
Informed Consent | 3 | 2011 | 274 | 0.160 |
Why?
|
Health Policy | 2 | 2011 | 184 | 0.160 |
Why?
|
Immunity, Innate | 1 | 2022 | 427 | 0.160 |
Why?
|
Laparoscopy | 1 | 2005 | 771 | 0.160 |
Why?
|
HIV Infections | 3 | 2012 | 829 | 0.160 |
Why?
|
Anastomosis, Surgical | 4 | 2006 | 273 | 0.160 |
Why?
|
Venous Thrombosis | 1 | 2021 | 250 | 0.160 |
Why?
|
Amino Acid Metabolism, Inborn Errors | 1 | 1998 | 11 | 0.160 |
Why?
|
Kidney Failure, Chronic | 3 | 2010 | 413 | 0.150 |
Why?
|
Urea | 1 | 1998 | 58 | 0.150 |
Why?
|
Ammonia | 1 | 1998 | 38 | 0.150 |
Why?
|
Donor Selection | 2 | 2018 | 74 | 0.150 |
Why?
|
Cultural Characteristics | 2 | 2015 | 18 | 0.150 |
Why?
|
Body Mass Index | 2 | 2019 | 763 | 0.150 |
Why?
|
Tomography, X-Ray Computed | 4 | 2008 | 2644 | 0.140 |
Why?
|
Gallbladder | 1 | 1997 | 31 | 0.140 |
Why?
|
Occlusive Dressings | 1 | 1996 | 7 | 0.140 |
Why?
|
Laparotomy | 2 | 2007 | 65 | 0.140 |
Why?
|
Chicago | 5 | 2021 | 1416 | 0.140 |
Why?
|
Polytetrafluoroethylene | 1 | 1996 | 74 | 0.140 |
Why?
|
Liver Cirrhosis | 4 | 2010 | 254 | 0.140 |
Why?
|
Cyclosporins | 6 | 1991 | 58 | 0.140 |
Why?
|
Biliary Atresia | 4 | 1995 | 22 | 0.140 |
Why?
|
Cholangiocarcinoma | 3 | 2010 | 76 | 0.140 |
Why?
|
Antibodies, Monoclonal | 5 | 2004 | 1399 | 0.130 |
Why?
|
Stomach | 2 | 2006 | 111 | 0.130 |
Why?
|
Tissue Preservation | 1 | 2015 | 14 | 0.130 |
Why?
|
Gift Giving | 1 | 2015 | 5 | 0.130 |
Why?
|
Social Control, Formal | 1 | 2015 | 12 | 0.130 |
Why?
|
Volition | 1 | 2015 | 15 | 0.130 |
Why?
|
Steroids | 1 | 1996 | 174 | 0.120 |
Why?
|
Pentanoic Acids | 1 | 2014 | 6 | 0.120 |
Why?
|
Cholangitis, Sclerosing | 2 | 2013 | 51 | 0.120 |
Why?
|
United States | 8 | 2021 | 6905 | 0.120 |
Why?
|
Biotin | 1 | 2014 | 45 | 0.120 |
Why?
|
International Agencies | 1 | 2014 | 35 | 0.120 |
Why?
|
Mixed Tumor, Malignant | 1 | 1994 | 4 | 0.120 |
Why?
|
Universities | 1 | 2015 | 146 | 0.120 |
Why?
|
Surface-Active Agents | 1 | 2014 | 60 | 0.120 |
Why?
|
Body Height | 1 | 2014 | 100 | 0.120 |
Why?
|
Carcinosarcoma | 1 | 1994 | 21 | 0.120 |
Why?
|
Mycophenolic Acid | 3 | 1998 | 84 | 0.110 |
Why?
|
Colectomy | 3 | 2007 | 172 | 0.110 |
Why?
|
Transplantation Immunology | 1 | 2014 | 82 | 0.110 |
Why?
|
Aged | 14 | 2016 | 18988 | 0.110 |
Why?
|
Health Behavior | 1 | 2015 | 184 | 0.110 |
Why?
|
Surgical Flaps | 2 | 2013 | 249 | 0.110 |
Why?
|
Tissue and Organ Harvesting | 2 | 2007 | 78 | 0.110 |
Why?
|
Heart Transplantation | 6 | 2008 | 716 | 0.110 |
Why?
|
Morphogenesis | 1 | 2014 | 206 | 0.110 |
Why?
|
Cadaver | 4 | 2002 | 185 | 0.110 |
Why?
|
Cryopreservation | 1 | 2013 | 74 | 0.110 |
Why?
|
Liver Function Tests | 3 | 1997 | 92 | 0.110 |
Why?
|
Monitoring, Immunologic | 1 | 2012 | 17 | 0.100 |
Why?
|
International Cooperation | 2 | 2011 | 125 | 0.100 |
Why?
|
Opportunistic Infections | 2 | 2010 | 59 | 0.100 |
Why?
|
Capital Punishment | 1 | 2011 | 3 | 0.100 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 2 | 1989 | 97 | 0.100 |
Why?
|
Rats, Inbred Lew | 3 | 2010 | 193 | 0.100 |
Why?
|
Animals | 13 | 2022 | 27260 | 0.100 |
Why?
|
Coinfection | 1 | 2012 | 58 | 0.100 |
Why?
|
Hepatoblastoma | 2 | 2010 | 12 | 0.100 |
Why?
|
Models, Theoretical | 1 | 2014 | 490 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2013 | 170 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 2 | 2013 | 343 | 0.100 |
Why?
|
Hepatitis C, Chronic | 1 | 2012 | 91 | 0.100 |
Why?
|
Pancreatic Neoplasms | 2 | 1994 | 666 | 0.100 |
Why?
|
Liver Regeneration | 1 | 2011 | 36 | 0.100 |
Why?
|
Tumor Virus Infections | 2 | 2005 | 81 | 0.090 |
Why?
|
Platelet Count | 1 | 2011 | 93 | 0.090 |
Why?
|
Death | 1 | 2011 | 85 | 0.090 |
Why?
|
Fascia | 1 | 2010 | 30 | 0.090 |
Why?
|
Hyperoxaluria | 1 | 2010 | 26 | 0.090 |
Why?
|
Hepatic Encephalopathy | 2 | 2001 | 39 | 0.090 |
Why?
|
Hemangioendothelioma | 1 | 2010 | 9 | 0.090 |
Why?
|
Survival Analysis | 8 | 2012 | 1534 | 0.090 |
Why?
|
Incidence | 6 | 2012 | 1588 | 0.090 |
Why?
|
Capsules | 1 | 2010 | 37 | 0.090 |
Why?
|
Alginates | 1 | 2010 | 16 | 0.090 |
Why?
|
Polylysine | 1 | 2010 | 34 | 0.090 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 526 | 0.090 |
Why?
|
Gene Expression Regulation | 1 | 2019 | 1974 | 0.090 |
Why?
|
Tumor Necrosis Factor-alpha | 5 | 1991 | 699 | 0.090 |
Why?
|
Costs and Cost Analysis | 3 | 2021 | 153 | 0.090 |
Why?
|
Transplantation Tolerance | 1 | 2011 | 133 | 0.090 |
Why?
|
Enterococcus | 2 | 2001 | 35 | 0.090 |
Why?
|
Antibodies | 4 | 2000 | 353 | 0.090 |
Why?
|
Radiography | 3 | 2007 | 808 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 1936 | 0.090 |
Why?
|
Young Adult | 6 | 2019 | 6257 | 0.090 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 1989 | 394 | 0.090 |
Why?
|
Resuscitation | 2 | 2022 | 105 | 0.080 |
Why?
|
Interferon-gamma | 1 | 2011 | 451 | 0.080 |
Why?
|
ABO Blood-Group System | 2 | 2008 | 58 | 0.080 |
Why?
|
Drug Compounding | 1 | 2010 | 80 | 0.080 |
Why?
|
Age Factors | 5 | 2019 | 1861 | 0.080 |
Why?
|
Sensitivity and Specificity | 3 | 2019 | 2012 | 0.080 |
Why?
|
Sarcoma | 1 | 2010 | 219 | 0.080 |
Why?
|
Illinois | 2 | 2002 | 469 | 0.080 |
Why?
|
Neuroendocrine Tumors | 1 | 2010 | 117 | 0.080 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2008 | 35 | 0.080 |
Why?
|
Organ Preservation | 3 | 2022 | 105 | 0.080 |
Why?
|
Documentation | 1 | 2009 | 103 | 0.080 |
Why?
|
Amikacin | 1 | 2007 | 5 | 0.080 |
Why?
|
Blood Group Incompatibility | 1 | 2008 | 19 | 0.080 |
Why?
|
C-Peptide | 2 | 2018 | 179 | 0.080 |
Why?
|
Ciprofloxacin | 1 | 2007 | 29 | 0.080 |
Why?
|
Guanine | 1 | 2008 | 207 | 0.080 |
Why?
|
Kidney Diseases | 3 | 2005 | 319 | 0.080 |
Why?
|
Lymphoproliferative Disorders | 3 | 2001 | 111 | 0.070 |
Why?
|
Rats | 6 | 2010 | 4039 | 0.070 |
Why?
|
Body Weight | 2 | 2014 | 452 | 0.070 |
Why?
|
Biopsy | 5 | 1999 | 1180 | 0.070 |
Why?
|
Iliac Vein | 1 | 2007 | 30 | 0.070 |
Why?
|
Pseudomonas Infections | 1 | 2007 | 99 | 0.070 |
Why?
|
Creatinine | 5 | 1999 | 293 | 0.070 |
Why?
|
Health Care Rationing | 2 | 2004 | 83 | 0.070 |
Why?
|
Iliac Artery | 1 | 2007 | 38 | 0.070 |
Why?
|
Acne Vulgaris | 1 | 2007 | 35 | 0.070 |
Why?
|
Prednisone | 5 | 1998 | 258 | 0.070 |
Why?
|
Splenic Artery | 1 | 2006 | 11 | 0.070 |
Why?
|
Rare Diseases | 1 | 2007 | 64 | 0.070 |
Why?
|
Aorta, Abdominal | 1 | 2006 | 59 | 0.070 |
Why?
|
Length of Stay | 3 | 2001 | 728 | 0.070 |
Why?
|
Intestinal Perforation | 1 | 2006 | 35 | 0.070 |
Why?
|
Pressure | 1 | 2007 | 165 | 0.070 |
Why?
|
Medical Oncology | 1 | 2010 | 379 | 0.070 |
Why?
|
Ethics, Medical | 1 | 2009 | 307 | 0.070 |
Why?
|
Pseudomonas aeruginosa | 1 | 2007 | 201 | 0.070 |
Why?
|
Neoplasm Metastasis | 1 | 2010 | 1107 | 0.070 |
Why?
|
Risk Assessment | 2 | 2019 | 2284 | 0.070 |
Why?
|
Polypropylenes | 1 | 2005 | 23 | 0.070 |
Why?
|
Transplantation, Autologous | 2 | 2018 | 342 | 0.070 |
Why?
|
Anal Canal | 1 | 2006 | 88 | 0.070 |
Why?
|
Blood Glucose | 3 | 2018 | 835 | 0.070 |
Why?
|
Necrosis | 1 | 2006 | 209 | 0.070 |
Why?
|
Biopsy, Needle | 3 | 1998 | 233 | 0.070 |
Why?
|
Risk Factors | 10 | 2012 | 5442 | 0.060 |
Why?
|
Drug Resistance | 2 | 1996 | 232 | 0.060 |
Why?
|
Anesthesia, General | 1 | 2006 | 116 | 0.060 |
Why?
|
Chronic Disease | 4 | 2008 | 946 | 0.060 |
Why?
|
BK Virus | 1 | 2005 | 23 | 0.060 |
Why?
|
Polyomavirus Infections | 1 | 2005 | 28 | 0.060 |
Why?
|
Isoxazoles | 1 | 2005 | 77 | 0.060 |
Why?
|
Disease Susceptibility | 1 | 2005 | 199 | 0.060 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2013 | 1174 | 0.060 |
Why?
|
Acute Disease | 4 | 1999 | 837 | 0.060 |
Why?
|
Nephrectomy | 1 | 2007 | 293 | 0.060 |
Why?
|
Cohort Studies | 3 | 2018 | 2845 | 0.060 |
Why?
|
California | 3 | 1997 | 143 | 0.060 |
Why?
|
Mice | 4 | 2022 | 11718 | 0.060 |
Why?
|
Biocompatible Materials | 1 | 2005 | 198 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2010 | 1214 | 0.060 |
Why?
|
Cell Separation | 1 | 2004 | 198 | 0.060 |
Why?
|
Hospitals, University | 3 | 1999 | 195 | 0.060 |
Why?
|
Cell Culture Techniques | 1 | 2004 | 192 | 0.050 |
Why?
|
Thermodynamics | 1 | 2004 | 310 | 0.050 |
Why?
|
Surgical Procedures, Operative | 1 | 2005 | 205 | 0.050 |
Why?
|
Canada | 2 | 2007 | 207 | 0.050 |
Why?
|
Decision Support Techniques | 1 | 2004 | 168 | 0.050 |
Why?
|
Organ Size | 2 | 2014 | 368 | 0.050 |
Why?
|
Pain, Postoperative | 1 | 2005 | 251 | 0.050 |
Why?
|
Temperature | 1 | 2004 | 399 | 0.050 |
Why?
|
Cell Line, Transformed | 1 | 2002 | 155 | 0.050 |
Why?
|
Adrenal Cortex Hormones | 2 | 1998 | 265 | 0.050 |
Why?
|
Virus Replication | 2 | 2022 | 319 | 0.050 |
Why?
|
Antilymphocyte Serum | 5 | 2004 | 70 | 0.050 |
Why?
|
Intracranial Pressure | 1 | 2002 | 87 | 0.050 |
Why?
|
Colorectal Neoplasms | 2 | 2000 | 980 | 0.050 |
Why?
|
Biomarkers, Tumor | 1 | 2010 | 1530 | 0.050 |
Why?
|
Regional Blood Flow | 1 | 2002 | 198 | 0.050 |
Why?
|
Bilirubin | 3 | 1999 | 129 | 0.050 |
Why?
|
A549 Cells | 1 | 2022 | 41 | 0.050 |
Why?
|
Iatrogenic Disease | 1 | 2002 | 70 | 0.050 |
Why?
|
Vero Cells | 1 | 2022 | 101 | 0.050 |
Why?
|
Virus Internalization | 1 | 2022 | 39 | 0.050 |
Why?
|
Drug Administration Schedule | 4 | 1998 | 894 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2013 | 6754 | 0.050 |
Why?
|
Constriction, Pathologic | 1 | 2002 | 218 | 0.050 |
Why?
|
Insulin | 3 | 2018 | 1145 | 0.050 |
Why?
|
Cardiotonic Agents | 1 | 2002 | 89 | 0.050 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 2002 | 51 | 0.050 |
Why?
|
Vancomycin Resistance | 1 | 2001 | 18 | 0.050 |
Why?
|
Respiratory Insufficiency | 2 | 2001 | 159 | 0.050 |
Why?
|
Endoplasmic Reticulum Stress | 1 | 2022 | 85 | 0.050 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2022 | 91 | 0.050 |
Why?
|
Interferons | 1 | 2022 | 124 | 0.050 |
Why?
|
Constriction | 1 | 2001 | 27 | 0.050 |
Why?
|
Biological Availability | 2 | 1998 | 92 | 0.050 |
Why?
|
Bile | 2 | 2001 | 57 | 0.050 |
Why?
|
Endoribonucleases | 1 | 2022 | 92 | 0.050 |
Why?
|
Hepatitis, Autoimmune | 1 | 2001 | 19 | 0.050 |
Why?
|
Severity of Illness Index | 1 | 2007 | 1834 | 0.050 |
Why?
|
Cerebrovascular Circulation | 1 | 2002 | 227 | 0.050 |
Why?
|
Positive-Pressure Respiration | 1 | 2001 | 41 | 0.050 |
Why?
|
Foreign-Body Migration | 1 | 2001 | 39 | 0.050 |
Why?
|
Antimetabolites | 1 | 2000 | 24 | 0.050 |
Why?
|
Biliary Tract Neoplasms | 1 | 2000 | 33 | 0.050 |
Why?
|
Heart Rate | 1 | 2002 | 492 | 0.040 |
Why?
|
Immunotherapy | 2 | 1999 | 663 | 0.040 |
Why?
|
Neurosurgical Procedures | 1 | 2022 | 232 | 0.040 |
Why?
|
Respiratory Tract Diseases | 1 | 2000 | 45 | 0.040 |
Why?
|
Autoantibodies | 1 | 2001 | 268 | 0.040 |
Why?
|
Computed Tomography Angiography | 1 | 2021 | 140 | 0.040 |
Why?
|
Intraoperative Period | 2 | 1997 | 90 | 0.040 |
Why?
|
Transplantation, Heterologous | 1 | 2021 | 370 | 0.040 |
Why?
|
Hepatitis, Alcoholic | 1 | 1999 | 16 | 0.040 |
Why?
|
Fatal Outcome | 2 | 2010 | 295 | 0.040 |
Why?
|
Cell Transplantation | 1 | 1999 | 47 | 0.040 |
Why?
|
Mice, Nude | 1 | 2021 | 814 | 0.040 |
Why?
|
Program Evaluation | 1 | 2000 | 303 | 0.040 |
Why?
|
Blood Pressure | 1 | 2002 | 894 | 0.040 |
Why?
|
Emulsions | 1 | 1998 | 19 | 0.040 |
Why?
|
North America | 1 | 2018 | 184 | 0.040 |
Why?
|
Nutrition Surveys | 1 | 2019 | 109 | 0.040 |
Why?
|
Carbamoyl-Phosphate Synthase (Ammonia) | 1 | 1998 | 4 | 0.040 |
Why?
|
Ornithine Carbamoyltransferase Deficiency Disease | 1 | 1998 | 4 | 0.040 |
Why?
|
Cytokines | 1 | 2022 | 801 | 0.040 |
Why?
|
Citrulline | 1 | 1998 | 10 | 0.040 |
Why?
|
Communication Disorders | 1 | 1998 | 7 | 0.040 |
Why?
|
Diagnosis, Differential | 3 | 2010 | 1589 | 0.040 |
Why?
|
Anticoagulants | 1 | 2001 | 425 | 0.040 |
Why?
|
Epithelial Cells | 1 | 2022 | 688 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2001 | 1354 | 0.040 |
Why?
|
Multivariate Analysis | 3 | 2010 | 985 | 0.040 |
Why?
|
Alcoholism | 1 | 1999 | 178 | 0.040 |
Why?
|
Microcephaly | 1 | 1998 | 76 | 0.040 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 1998 | 50 | 0.040 |
Why?
|
Vancomycin | 1 | 1998 | 73 | 0.040 |
Why?
|
Glucose Tolerance Test | 1 | 2018 | 227 | 0.040 |
Why?
|
Coccidioidomycosis | 1 | 1997 | 7 | 0.040 |
Why?
|
Dosage Forms | 1 | 1996 | 7 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2021 | 1712 | 0.030 |
Why?
|
Genetic Therapy | 1 | 1999 | 369 | 0.030 |
Why?
|
Intellectual Disability | 1 | 1998 | 189 | 0.030 |
Why?
|
Methylprednisolone | 1 | 1996 | 64 | 0.030 |
Why?
|
Cardiac Surgical Procedures | 1 | 2001 | 474 | 0.030 |
Why?
|
Syndrome | 1 | 1997 | 449 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 1996 | 119 | 0.030 |
Why?
|
Oxygen | 1 | 2001 | 742 | 0.030 |
Why?
|
Quality of Life | 3 | 1996 | 1655 | 0.030 |
Why?
|
Situs Inversus | 1 | 1995 | 15 | 0.030 |
Why?
|
Sex Factors | 1 | 2019 | 1062 | 0.030 |
Why?
|
Pancreatic Function Tests | 1 | 2015 | 7 | 0.030 |
Why?
|
Somatostatin-Secreting Cells | 1 | 2015 | 7 | 0.030 |
Why?
|
Public Opinion | 1 | 2015 | 42 | 0.030 |
Why?
|
Glucagon-Secreting Cells | 1 | 2015 | 25 | 0.030 |
Why?
|
Logistic Models | 1 | 2018 | 1207 | 0.030 |
Why?
|
Altruism | 1 | 2015 | 34 | 0.030 |
Why?
|
Hepatitis, Viral, Human | 2 | 1999 | 23 | 0.030 |
Why?
|
Administration, Oral | 1 | 1996 | 681 | 0.030 |
Why?
|
Carbocyanines | 1 | 2014 | 18 | 0.030 |
Why?
|
Succinimides | 1 | 2014 | 12 | 0.030 |
Why?
|
Streptavidin | 1 | 2014 | 14 | 0.030 |
Why?
|
Intestine, Small | 1 | 1996 | 299 | 0.030 |
Why?
|
Tissue Survival | 1 | 2014 | 13 | 0.030 |
Why?
|
Age of Onset | 1 | 2015 | 312 | 0.030 |
Why?
|
Tissue Culture Techniques | 1 | 2014 | 81 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2011 | 776 | 0.030 |
Why?
|
Cell Communication | 1 | 2014 | 199 | 0.030 |
Why?
|
Celiac Plexus | 1 | 1993 | 3 | 0.030 |
Why?
|
Hepatitis B virus | 2 | 2008 | 43 | 0.030 |
Why?
|
Nerve Compression Syndromes | 1 | 1993 | 18 | 0.030 |
Why?
|
Leiomyosarcoma | 1 | 1994 | 45 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 374 | 0.030 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 36 | 0.030 |
Why?
|
Pilot Projects | 2 | 2011 | 865 | 0.030 |
Why?
|
Family | 1 | 1995 | 325 | 0.030 |
Why?
|
Swine | 1 | 2014 | 581 | 0.030 |
Why?
|
Cell Adhesion | 1 | 2014 | 425 | 0.030 |
Why?
|
Recurrence | 4 | 1998 | 1136 | 0.030 |
Why?
|
Cell- and Tissue-Based Therapy | 1 | 2013 | 50 | 0.030 |
Why?
|
Hemorrhage | 2 | 2000 | 277 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2013 | 192 | 0.030 |
Why?
|
Azathioprine | 3 | 1998 | 124 | 0.030 |
Why?
|
Abdomen, Acute | 1 | 2012 | 20 | 0.030 |
Why?
|
Cholestasis | 1 | 1992 | 45 | 0.030 |
Why?
|
T-Lymphocytes | 2 | 1989 | 1222 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 1995 | 384 | 0.030 |
Why?
|
Medical Tourism | 1 | 2011 | 5 | 0.030 |
Why?
|
Immunoassay | 1 | 2012 | 91 | 0.030 |
Why?
|
CD3 Complex | 2 | 1989 | 134 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2013 | 171 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2013 | 205 | 0.030 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2011 | 8 | 0.030 |
Why?
|
Drainage | 3 | 1998 | 158 | 0.020 |
Why?
|
Immunity, Cellular | 1 | 2012 | 178 | 0.020 |
Why?
|
Inflammatory Bowel Diseases | 1 | 1998 | 570 | 0.020 |
Why?
|
Advisory Committees | 1 | 2011 | 88 | 0.020 |
Why?
|
Hepacivirus | 1 | 2012 | 129 | 0.020 |
Why?
|
Algorithms | 2 | 2014 | 1870 | 0.020 |
Why?
|
Colitis, Ulcerative | 2 | 2013 | 733 | 0.020 |
Why?
|
Drug Therapy, Combination | 3 | 1998 | 780 | 0.020 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2010 | 33 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 1998 | 738 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2010 | 67 | 0.020 |
Why?
|
alpha-Fetoproteins | 1 | 2010 | 43 | 0.020 |
Why?
|
Brain Death | 1 | 2011 | 82 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2015 | 1795 | 0.020 |
Why?
|
Chemoprevention | 1 | 2010 | 92 | 0.020 |
Why?
|
Hypertonic Solutions | 1 | 1990 | 17 | 0.020 |
Why?
|
Abdomen | 1 | 2010 | 122 | 0.020 |
Why?
|
Organ Preservation Solutions | 1 | 1990 | 28 | 0.020 |
Why?
|
Solutions | 1 | 1990 | 85 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 2011 | 995 | 0.020 |
Why?
|
Adenocarcinoma | 2 | 1994 | 1193 | 0.020 |
Why?
|
Blood Transfusion | 1 | 1990 | 165 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 1711 | 0.020 |
Why?
|
Kidney Tubular Necrosis, Acute | 2 | 1999 | 9 | 0.020 |
Why?
|
Portasystemic Shunt, Surgical | 1 | 1989 | 12 | 0.020 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 1989 | 44 | 0.020 |
Why?
|
Portoenterostomy, Hepatic | 1 | 1988 | 3 | 0.020 |
Why?
|
Random Allocation | 1 | 1989 | 328 | 0.020 |
Why?
|
Rupture | 1 | 2008 | 61 | 0.020 |
Why?
|
Aspergillosis | 1 | 1988 | 41 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 858 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2010 | 848 | 0.020 |
Why?
|
Methylprednisolone Hemisuccinate | 2 | 1998 | 10 | 0.020 |
Why?
|
DNA, Viral | 1 | 2008 | 261 | 0.020 |
Why?
|
Infant, Newborn | 3 | 1998 | 2455 | 0.020 |
Why?
|
Cell Differentiation | 1 | 1994 | 1521 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2014 | 3201 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2013 | 1233 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2010 | 540 | 0.020 |
Why?
|
Rats, Inbred BUF | 3 | 1991 | 4 | 0.020 |
Why?
|
Los Angeles | 2 | 1996 | 28 | 0.020 |
Why?
|
Angiography | 1 | 2006 | 208 | 0.020 |
Why?
|
Crotonates | 1 | 2005 | 12 | 0.020 |
Why?
|
Toluidines | 1 | 2005 | 18 | 0.020 |
Why?
|
Combined Modality Therapy | 3 | 1995 | 1707 | 0.020 |
Why?
|
Hydroxybutyrates | 1 | 2005 | 27 | 0.020 |
Why?
|
Aniline Compounds | 1 | 2005 | 58 | 0.020 |
Why?
|
Nitriles | 1 | 2005 | 160 | 0.020 |
Why?
|
Receptors, Interleukin-2 | 1 | 2004 | 67 | 0.010 |
Why?
|
Esophageal and Gastric Varices | 2 | 1998 | 34 | 0.010 |
Why?
|
Urinary Bladder | 2 | 1996 | 246 | 0.010 |
Why?
|
Lymphocyte Depletion | 1 | 2004 | 98 | 0.010 |
Why?
|
Small-Area Analysis | 1 | 2003 | 8 | 0.010 |
Why?
|
Health Priorities | 1 | 2003 | 22 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 1989 | 1146 | 0.010 |
Why?
|
Geography | 1 | 2003 | 227 | 0.010 |
Why?
|
Neoplasm Staging | 2 | 2000 | 1988 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2004 | 430 | 0.010 |
Why?
|
Environmental Microbiology | 1 | 2001 | 22 | 0.010 |
Why?
|
Portal System | 1 | 2001 | 13 | 0.010 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 1998 | 237 | 0.010 |
Why?
|
Government Regulation | 1 | 2001 | 49 | 0.010 |
Why?
|
Focal Nodular Hyperplasia | 1 | 2001 | 10 | 0.010 |
Why?
|
Models, Statistical | 1 | 2004 | 575 | 0.010 |
Why?
|
Hamartoma | 1 | 2001 | 34 | 0.010 |
Why?
|
Cytomegalovirus Infections | 1 | 2001 | 146 | 0.010 |
Why?
|
DNA, Bacterial | 1 | 2001 | 242 | 0.010 |
Why?
|
Hemangioma | 1 | 2001 | 64 | 0.010 |
Why?
|
Rats, Inbred Strains | 2 | 1990 | 312 | 0.010 |
Why?
|
Lymphotoxin-alpha | 2 | 1990 | 44 | 0.010 |
Why?
|
Population Surveillance | 1 | 2001 | 216 | 0.010 |
Why?
|
Alanine Transaminase | 2 | 1990 | 71 | 0.010 |
Why?
|
Aspartate Aminotransferases | 2 | 1990 | 74 | 0.010 |
Why?
|
Cysts | 1 | 2001 | 106 | 0.010 |
Why?
|
Feces | 1 | 2001 | 327 | 0.010 |
Why?
|
Fibrosis | 1 | 2001 | 233 | 0.010 |
Why?
|
Risk | 1 | 2001 | 657 | 0.010 |
Why?
|
Cell Division | 1 | 2001 | 695 | 0.010 |
Why?
|
Autoimmune Diseases | 1 | 2001 | 249 | 0.010 |
Why?
|
Radiography, Thoracic | 1 | 2001 | 319 | 0.010 |
Why?
|
Adenoma | 1 | 2001 | 246 | 0.010 |
Why?
|
Plasmapheresis | 1 | 1998 | 25 | 0.010 |
Why?
|
Pregnancy | 2 | 2001 | 3000 | 0.010 |
Why?
|
Pneumonia | 1 | 2000 | 182 | 0.010 |
Why?
|
Drug Resistance, Microbial | 1 | 1998 | 75 | 0.010 |
Why?
|
Aminosalicylic Acids | 1 | 1998 | 41 | 0.010 |
Why?
|
Gallbladder Diseases | 1 | 1998 | 23 | 0.010 |
Why?
|
Pregnancy Complications | 1 | 2001 | 345 | 0.010 |
Why?
|
Lung Diseases | 1 | 2000 | 269 | 0.010 |
Why?
|
Urinary Retention | 1 | 1997 | 42 | 0.010 |
Why?
|
Complement C3 | 1 | 1997 | 58 | 0.010 |
Why?
|
Radiology, Interventional | 1 | 1998 | 68 | 0.010 |
Why?
|
Renal Insufficiency | 1 | 1998 | 98 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 1997 | 66 | 0.010 |
Why?
|
Fluconazole | 1 | 1997 | 10 | 0.010 |
Why?
|
Fibrin | 1 | 1997 | 86 | 0.010 |
Why?
|
Amphotericin B | 1 | 1997 | 34 | 0.010 |
Why?
|
Capillaries | 1 | 1997 | 90 | 0.010 |
Why?
|
Bacteremia | 1 | 1998 | 102 | 0.010 |
Why?
|
Kidney Glomerulus | 1 | 1997 | 122 | 0.010 |
Why?
|
Histocompatibility Testing | 1 | 1996 | 137 | 0.010 |
Why?
|
Treatment Failure | 1 | 1997 | 286 | 0.010 |
Why?
|
Neutrophils | 1 | 1997 | 308 | 0.010 |
Why?
|
Bone Diseases | 1 | 1995 | 57 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 1997 | 463 | 0.010 |
Why?
|
Diabetic Nephropathies | 1 | 1995 | 87 | 0.010 |
Why?
|
Salvage Therapy | 1 | 1996 | 235 | 0.010 |
Why?
|
Safety | 1 | 1995 | 149 | 0.010 |
Why?
|
Glucocorticoids | 1 | 1997 | 356 | 0.010 |
Why?
|
Extremities | 1 | 1995 | 167 | 0.010 |
Why?
|
Immunization, Passive | 1 | 1994 | 71 | 0.010 |
Why?
|
Emergencies | 1 | 1995 | 120 | 0.010 |
Why?
|
Postoperative Care | 1 | 1995 | 228 | 0.010 |
Why?
|
Ischemia | 1 | 1995 | 251 | 0.010 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 1993 | 33 | 0.010 |
Why?
|
Choledochostomy | 1 | 1992 | 8 | 0.010 |
Why?
|
Cholestasis, Intrahepatic | 1 | 1992 | 14 | 0.010 |
Why?
|
Anastomosis, Roux-en-Y | 1 | 1992 | 26 | 0.010 |
Why?
|
Therapeutic Irrigation | 1 | 1992 | 61 | 0.010 |
Why?
|
Dilatation | 1 | 1992 | 48 | 0.010 |
Why?
|
Immune Sera | 1 | 1991 | 52 | 0.010 |
Why?
|
Adenoma, Bile Duct | 1 | 1990 | 4 | 0.010 |
Why?
|
Rats, Inbred BN | 1 | 1990 | 38 | 0.010 |
Why?
|
Immunologic Techniques | 1 | 1990 | 26 | 0.010 |
Why?
|
Transplantation, Isogeneic | 1 | 1990 | 39 | 0.010 |
Why?
|
Raffinose | 1 | 1990 | 23 | 0.010 |
Why?
|
Leukocyte Count | 1 | 1990 | 223 | 0.010 |
Why?
|
Allopurinol | 1 | 1990 | 77 | 0.010 |
Why?
|
Glutathione | 1 | 1990 | 108 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 1995 | 703 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 1991 | 1011 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1989 | 270 | 0.010 |
Why?
|
Analysis of Variance | 1 | 1990 | 901 | 0.000 |
Why?
|
Occupations | 1 | 1988 | 25 | 0.000 |
Why?
|
Adenosine | 1 | 1990 | 237 | 0.000 |
Why?
|
Activities of Daily Living | 1 | 1988 | 207 | 0.000 |
Why?
|
Patient Acceptance of Health Care | 1 | 1988 | 255 | 0.000 |
Why?
|